BPC-157 vs Relaxin-2 (Serelaxin)
The "Wolverine peptide" known for its remarkable healing properties across tendons, ligaments, muscles, and the gut.
Recombinant human relaxin-2 studied for acute heart failure recovery and cardiovascular support
Quick comparison
Dose range
BPC-157
250–500 mcg
Relaxin-2 (Serelaxin)
30–30 mcg/kg/day
Frequency
BPC-157
Once daily
Relaxin-2 (Serelaxin)
Once daily
Administration
BPC-157
Subcutaneous injection
Relaxin-2 (Serelaxin)
Intravenous (IV) infusion
Cycle length
BPC-157
4-6 weeks
Relaxin-2 (Serelaxin)
8-12 weeks
Onset speed
BPC-157
Moderate (1-2 weeks)
Relaxin-2 (Serelaxin)
Moderate (1-2 weeks)
Evidence level
BPC-157
Strong preclinical (extensive animal studies)
Relaxin-2 (Serelaxin)
Limited human trials
Benefit ratings
Primary Benefit
Secondary Benefit
Additional Benefit
Cardiovascular Function
Heart Failure Support
Acute Medical Management
Compound specifications
BPC-157
Molecular formula
C62H98N16O22
Molecular weight
1419.53 g/mol
Half-life
4-6 hours
Bioavailability
~100% (subcutaneous)
CAS number
137525-51-0
Relaxin-2 (Serelaxin)
Molecular formula
C256H408N74O74S8
Molecular weight
5,963 Da (Daltons)
Half-life
Varies by route of administration
Bioavailability
Varies by route of administration
CAS number
See PubChem for identifiers
Dosing compared
BPC-157
Subcutaneous
250 mcg
Once daily · 1-2 weeks
A common starting amount in research practice, often injected near the injured area. BPC-157 has no human dose-finding trials, so doses come from animal studies and documented practice [1][2].
250-500 mcg
Twice daily · 4-6 weeks
Commonly used range for tissue and tendon recovery in research practice [1][3].
500 mcg
Twice daily · 6-8 weeks
Upper end used in practice for more demanding acute injuries [1][3].
Relaxin-2 (Serelaxin)
Intravenous
30 mcg/kg/day
Continuous IV infusion · 48 hours
Weight-adjusted continuous IV infusion used across the RELAX-AHF programme for acute heart failure; improved dyspnea but did not reduce mortality in RELAX-AHF-2 [3][5]. Hospital administration only.
Best suited for
BPC-157
Tendon and ligament injuries
Sprains, strains, tears, tendinitis - BPC-157 accelerates collagen synthesis and tissue repair
Gut healing
IBS, leaky gut, ulcers, inflammatory bowel conditions - derived from gastric juice, it has a natural affinity for digestive tissue
Muscle injuries
Strains, post-workout recovery, chronic muscle issues - promotes angiogenesis and growth factor expression
Joint problems
Arthritis support, joint pain, cartilage issues - anti-inflammatory and regenerative properties
Post-surgical recovery
Accelerating healing after procedures - works systemically to enhance the body's repair mechanisms
Relaxin-2 (Serelaxin)
Acute heart failure symptom management
Relaxin-2 (Serelaxin) is particularly effective for individuals focused on acute heart failure symptom management. Research supports its use in this area [5][9].
Cardiovascular recovery and support
Relaxin-2 (Serelaxin) is particularly effective for individuals focused on cardiovascular recovery and support. Research supports its use in this area [2].
Hospital-based therapeutic interventions
Relaxin-2 (Serelaxin) is particularly effective for individuals focused on hospital-based therapeutic interventions. Research supports its use in this area [3][15].
Side effects
BPC-157
Common
- Injection site redness
- Mild nausea
- Dizziness
Uncommon
- Headache
- Fatigue
- Hot/cold sensations
Serious
- Allergic reaction
Relaxin-2 (Serelaxin)
Common
- Hypotension (low blood pressure) - most common
- Tachycardia (increased heart rate)
- Headache
- Nausea
- Dizziness
- Peripheral edema (swelling)
- Increased creatinine levels
- Hyperkalemia (high potassium)
- Syncope (fainting)
- Atrial fibrillation
- Blood pressure checks every 2-4 hours during infusion
- Kidney function (creatinine and eGFR)
- Electrolytes, particularly potassium
- Heart rate and cardiac rhythm
- Urine output
Serious
- Severe cardiovascular events
Safety & evidence
BPC-157
Evidence level
Strong preclinical (extensive animal studies)
FDA status
Research compound
Safety overview
BPC-157 is a gastric pentadecapeptide with strong preclinical evidence from extensive animal studies spanning over 25 years of research. Critical limitation: BPC-157 has NOT completed Phase 3 human clinical trials. No FDA approval exists. Safety data comes primarily from rat and mouse studies, with only limited Phase 1-2 human data. Animal studies show no toxicity at therapeutic doses, but human data is insufficient for regulatory approval. The peptide is unregulated, and no standardized manufacturing or quality control requirements exist for research compounds. Individual responses may vary significantly, and serious medical supervision is essential before use, particularly if you have gastrointestinal conditions, take medications, or have pre-existing medical conditions.
Contraindications
- Pregnancy
- Breastfeeding
- Active cancer
- History of cancer
Relaxin-2 (Serelaxin)
Evidence level
Limited human trials
FDA status
Research compound
Safety overview
Serelaxin (recombinant relaxin-2) completed Phase III heart failure trials with favorable safety profile and cardiovascular benefit signals. [3][5][9] Hypotension occurs in 20-25% of subjects requiring hemodynamic monitoring; no serious adverse events directly attributable to serelaxin beyond expected vasodilatory effects. [11] Flushing and headaches mild and transient. No serious immunogenicity despite being recombinant human peptide; repeat dosing shows consistent response [12].
Contraindications
- Severe hypotension or hemodynamic instability
- Pregnancy (despite relaxin's natural role)
- Acute kidney injury or severe renal dysfunction
- Recent myocardial infarction (within 7 days)
- Uncontrolled arrhythmias
Which is right for you?
Choose BPC-157 if...
- Injury recovery
- Post-surgery healing
- Chronic pain management
- Gut health
Choose Relaxin-2 (Serelaxin) if...
- Acute heart failure symptom management
- Cardiovascular recovery and support
- Hospital-based therapeutic interventions